Condition
MSI-H Colorectal Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownPredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)NCT07327489 · 2025-04-14
RECRUITINGObservational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)NCT05520099 · 2023-06-26
ACTIVE_NOT_RECRUITINGNUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNCT05714553 · 2023-03-08
TERMINATEDImmunological Variables Associated to ICI Toxicity in Cancer PatientsNCT05429866 · 2022-09-01
UNKNOWNEfficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsNCT04802876 · 2021-04-12
ACTIVE_NOT_RECRUITINGA Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNCT04440943 · 2020-08-04
COMPLETEDA Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesNCT04244552 · 2020-02-11
TERMINATEDCommon interventions
ATRC-101BIOLOGICAL1BiopsyPROCEDURE1CDX-527DRUG1Checkpoint Blockade, ImmuneDRUG1Core Needle Biopsy, Forceps Biopsy, Punch BiopsyPROCEDURE1DocetaxelDRUG1Fosifloxuridine NafalbenamideDRUG1LeucovorinDRUG1Pegylated liposomal doxorubicin (PLD)DRUG1PembrolizumabBIOLOGICAL1PembrolizumabDRUG1SpartalizumabDRUG1TislelizumabDRUG1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING2
TERMINATED2
COMPLETED1
RECRUITING1
UNKNOWN1
Phase mix
PHASE13
PHASE23
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.